These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31852014)

  • 1. Health-related quality of life in Waldenstrom Macroglobulinemia and IgM-related disorders: A single institution experience.
    Frustaci AM; Nichelatti M; Deodato M; Zamprogna G; Minga P; Pioltelli ML; Cairoli R; Tedeschi A
    Hematol Oncol; 2020 Feb; 38(1):111-113. PubMed ID: 31852014
    [No Abstract]   [Full Text] [Related]  

  • 2. [Significance of monoclonal macroglobulinemia].
    Leporrier M
    Rev Prat; 1993 Feb; 43(3):298-301. PubMed ID: 8502959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Waldenström macroglobulinemia treatment algorithm 2018.
    Gertz MA
    Blood Cancer J; 2018 May; 8(4):40. PubMed ID: 29712895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders.
    Morra E; Cesana C; Klersy C; Barbarano L; Varettoni M; Cavanna L; Canesi B; Tresoldi E; Miqueleiz S; Bernuzzi P; Nosari AM; Lazzarino M
    Leukemia; 2004 Sep; 18(9):1512-7. PubMed ID: 15322559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance.
    Castillo JJ; Gertz MA
    Leuk Lymphoma; 2017 Apr; 58(4):773-780. PubMed ID: 27546465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.
    Tedeschi A; Conticello C; Rizzi R; Benevolo G; Laurenti L; Petrucci MT; Zaja F; Varettoni M
    Hematol Oncol; 2019 Apr; 37(2):117-128. PubMed ID: 30192023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral neuropathies associated with monoclonal proteins: a clinical review.
    Kelly JJ
    Muscle Nerve; 1985 Feb; 8(2):138-50. PubMed ID: 2997604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody activity of monoclonal immunoglobulins in myeloma, macroglobulinemia and benign gammapathy.
    Waldenström JG
    Med Oncol Tumor Pharmacother; 1986; 3(3-4):135-40. PubMed ID: 3100882
    [No Abstract]   [Full Text] [Related]  

  • 9. IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenström's macroglobulinemia (SWM).
    Kyle RA; Dispenzieri A; Kumar S; Larson D; Therneau T; Rajkumar SV
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):74-6. PubMed ID: 21454195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Subsets of T cells in myeloma, macroglobulinemia and benign monoclonal gammopathy: analysis of surface markers defined by monoclonal antibodies and the effect on Ig-synthesis by B cells].
    Okagawa K; Iguchi K; Iishi Y; Kosaka M
    Nihon Ketsueki Gakkai Zasshi; 1985 Aug; 48(5):1205-13. PubMed ID: 3934898
    [No Abstract]   [Full Text] [Related]  

  • 11. Paraproteinemic neuropathies.
    Vital A
    Brain Pathol; 2001 Oct; 11(4):399-407. PubMed ID: 11556684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropathies and paraproteins.
    Lunn MP
    Curr Opin Neurol; 2019 Oct; 32(5):658-665. PubMed ID: 31313705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and Prognosis of Patients with Immunoglobulin M Monoclonal Gammopathy.
    Tanaka H; Sakuma Y; Ikeda H; Shimizu R; Sugita Y; Iwai R
    J Clin Exp Hematop; 2017; 57(2):47-53. PubMed ID: 29021514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia.
    Atrash S; Zhang Q; Papanikolaou X; Stein C; Abdallah AO; Barlogie B
    J Glob Oncol; 2018 Sep; 4():1-8. PubMed ID: 30241189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.
    Mailankody S; Landgren O
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):187-193. PubMed ID: 27825465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When a Monoclonal Gammopathy Is Not Multiple Myeloma.
    Derman B; Castillo JJ; Sarosiek S; Beksac M
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-10. PubMed ID: 35394823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neurological manifestations of monoclonal gammopathies].
    Chassande B; Léger JM
    Rev Prat; 1993 Feb; 43(3):314-6. PubMed ID: 8389055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spectrum of IgM monoclonal gammopathy in 430 cases.
    Kyle RA; Garton JP
    Mayo Clin Proc; 1987 Aug; 62(8):719-31. PubMed ID: 3110508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predicting transformation of asymptomatic IgM monoclonal gammopathy.
    Greco A; Tedeschi A; Varettoni M; Nichelatti M; Paris L; Ricci F; Vismara E; Morra E
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):77-9. PubMed ID: 21454196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation and Management of Immunoglobulin M- and Waldenström-Associated Peripheral Neuropathies.
    Tomkins O; Leblond V; Lunn MP; Viala K; Weil DR; D'Sa S
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):761-776. PubMed ID: 37385714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.